斯芬哥辛-1-酸盐通过调节巨细胞两极分化和PI3k-Akt信号传递来缓解大肠炎
Liang Hu1, Zi Yang2,3, Ying Zhang1
1Outpatient Department of Oral and Maxillofacial Surgery, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Frontiers in immunology
|August 5, 2025
概括
在炎症性肠道疾病 (IBD) 的小鼠模型中,神素-1-酸盐 (S1P) 治疗减少了炎症并修复了肠道屏障完整性. S1P还调节了免疫细胞活性和关键信号通路,为IBD提供了潜在的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD) 涉及肠道屏障功能障碍和免疫调节障碍.
- 目前IBD的治疗方法在恢复肠道完整性和免疫平衡方面面临挑战.
- 斯芬哥辛-1-酸盐 (S1P) 在维持上皮质完整性方面表现有前途,但其在IBD中的作用尚未被探索.
研究的目的:
- 为了研究S1P在硫酸 (DSS) 诱导的大肠炎中的治疗潜力,IBD的一个模型.
- 评估S1P对肠道完整性,免疫细胞两极分化和潜在的分子机制的影响.
主要方法:
- 在C57BL/6小鼠中使用DSS诱导大肠炎.
- 小鼠接受了静脉注射S1P或载体注射.
- 评估了疾病活动,组织学分数,细胞亡,紧结蛋白表达和巨细胞两极分化.
- 用RNA测序来探索分子途径.
主要成果:
- S1P治疗显著缓解了DSS诱导的大肠炎,减少了炎症和.
- 通过增加E-cadherin和occludin的表达,S1P增强了肠道上皮质完整性.
- S1P抑制了M1巨细胞的两极分化,并促进了M2两极分化,同时降低了亡.
- RNA测序表明S1P调节的酸丁醇3-酶/蛋白酶B (PI3K-Akt) 和化学信号通路.
结论:
- 在实验性结肠炎中,S1P通过保持肠道屏障功能来证明治疗疗效.
- S1P通过巨细胞极化和化基因信号调节影响免疫反应.
- S1P对PI3K-Akt通路的调节有助于其在IBD中的保护作用.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
238
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
238
01:11IP3/DAG Signaling Pathway
12.4K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K
01:42Phosphoinositides and PIPs
8.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.7K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
190
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
190
01:21Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336